Covid-19 Update

Alistair Carmichael Excerpts

Monday 7th June 2021 Commons Chamber

[Matt Hancock]

Part of the purpose of the international testing regime is to get genetic sequences to spot variants, which we cannot do from a lateral flow test. That is the literal answer to my hon. Friend’s question. More broadly, the approach we are taking instead is to try to drive down the costs of PCR tests. Bringing a private market for PCR tests for travel has led to a significant reduction in cost, and that is another good example of harnessing private markets to improve people’s lives. The companies involved are strongly incentivised to deliver tests for a lower price. That is the approach we have taken for the reason I set out, and that is the decision we have made.

[Mr Alistair Carmichael (Orkney and Shetland) (LD)]

The Royal College of General Practitioners, the Doctors’ Association UK and the British Medical Association have all expressed concern about the adequacy of communication with patients about the proposals for data sharing. From the answer that the Secretary of State gave to the Opposition Front Bencher—the right hon. Member for Leicester South (Jonathan Ashworth)—and to my hon. Friend the Member for Twickenham (Munira Wilson), he obviously disagrees with that, but in the interests of making data-based decisions, can he tell the House what his Department is doing to assess the level of patient awareness about what will happen if they do not opt out by 23 June?

[Matt Hancock]

We are doing work in this area and talking to all the relevant bodies. Aside from some who have not yet understood the full importance of high-quality usage of data in the health system, actually, the vast majority of people, including the BMA, the Royal College of GPs and others, can see the benefit of getting this right. So we are working with them. The goal, though, is really clear—to use data better in the NHS because data saves lives.